Abbott Laboratories news from FiercePharma
News
AIDS foundation scolds Abbott
"Shame on Abbott" said the AIDS Healthcare Foundation, which is loudly calling into question the pricing policies of Abbott Laboratories in Mexico. Abbott, the Foundation claims, is picking on... Read more...
Abbott, AZ team up on Crestor
The battle of the cholesterol meds could heat up even further now that two Big Pharma companies have forged an alliance. AstraZeneca and Abbott Laboratories are joining forces to market Crestor,... Read more...
Justice probes biliary stent marketing
The U.S. Department of Justice has launched a probe of the bile-duct stent market, trying to determine whether companies such as Abbott Laboratories, Boston Scientific and Johnson & Johnson... Read more...
Abbott faces more AIDS suits
Lawsuits, lawsuits, lawsuits. Two drugmakers' hometown newspapers offer a rundown on the litigation they face over sales tactics: For AstraZeneca, it's allegations of improperly marketing Seroquel,... Read more...
FDA panel blesses new Enbrel use
The safety concerns recently raised about TNF blockers in general and Enbrel in particular weren't enough to keep the Amgen drug down. An FDA advisory panel voted 7-5 in favor of using Enbrel in... Read more...
Abbott's patent-tweaking draws fire
To your list of patent-lawsuits-to-watch, add a set of cases over TriCor, the Abbott Laboratories cholesterol med. TriCor is 33 years old, but it's still on patent, thanks to a series of formulation... Read more...
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
